Biontech stock
About BioNTech SE. BioNTech SE operates as immunotherapy company, which engages therapies for cancer and other serious diseases. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T Cells, TCRs and Next-Gen CP Immunomodulators. The company was founded by Christopher Huber, Oezlem Tuereci, and Ugur Sahin on June ...Interactive Chart for BioNTech SE (BNTX), analyze all the data with a huge range of indicators.
Did you know?
NTLA Intellia Therapeutics, Inc. +0.51%. EDIT Editas Medicine, Inc. NVO Novo Nordisk A/S. +1.25%. View the basic BNTX option chain and compare options of BioNTech SE on Yahoo Finance.BioNTech, founded in 2008 by Ugur Sahin and Özlem Türeci, is a German biotechnology company focused on developing individualized cancer immunotherapies and mRNA vaccines. The company's ... Complete BioNTech SE ADR stock information by Barron's. View real-time BNTX stock price and news, along with industry-best analysis.
Track BioNTech SE - ADR (BNTX) Stock Price, Quote, latest community messages, chart, news and other stock related information. Share your ideas and get valuable insights from the community of like minded traders and investorsWhy BioNTech Was a Sickly Stock This Week. Eric Volkman | Dec 30, 2022 The world is trying hard to get past the coronavirus pandemic, and investors are trying hard to get past coronavirus stocks.In addition, BioNTech SE Sponsored ADR has a VGM Score of D (this is a weighted average of the individual Style Scores which allow you to focus on the stocks that best fit your personal trading ...BioNTech SE(NASDAQ:BNTX): Amidst the biotech industry’s rapid growth and notable advancements, let’s analyze which of the two major players, ... Among the 386 stocks in the Biotech industry, MRNA is ranked #62, while BNTX is ranked #27. Beyond what is stated above, we have also rated the stocks for Value, Growth, ...
VIENNA STOCK EXCHANGE - BIONTECH SE ADR stocks (ISIN: US09075V1026) - price data, chart, performance & dividend for BIONTECH SE ADR.BioNTech SE (BNTX) is a publicly traded biotechnology business based in the US. It opened the day at $92.56 after a previous close of $91.67. During the day the price has varied from a low of $92.4132 to a high of $93.48. The latest price was $92.72 (25 minute delay). BioNTech is listed on the NASDAQ and employs 6,133 staff. ….
Reader Q&A - also see RECOMMENDED ARTICLES & FAQs. Biontech stock. Possible cause: Not clear biontech stock.
8 February 2024. BioNTech and Autolus Announce Strategic CAR-T Cell Therapy Collaboration to Advance Pipeline and Expand Late-Stage Programs. The press releases contained in this section of the website are provided for historical purposes only. The information contained in each press release is accurate only as of the date each …BioNTech SE is a Germany-based clinical-stage biotechnology company. The Company focuses on patient-specific immunotherapies for the treatment of cancer and other serious diseases. The Company is providing technologies including mRNA-based therapies, cell therapies, small molecules and antibodies, which can be utilized for …Mar 20, 2024 · BioNTech reported Q4 2023 earnings below expectations, with EPS at €1.90 vs. €9.26 last year. Sales were €1.479 billion, missing consensus. Guidance for 2024 anticipates revenues of €2.5 ...
Company profile page for BioNTech SE including stock price, company news, executives, board members, and contact information.BioNTech SE is a Germany-based clinical-stage biotechnology company. The Company focuses on patient-specific immunotherapies for the treatment of cancer and other serious diseases. The Company is providing technologies includ ing mRNA-based therapies, cell therapies, small molecules and antibodies, which can be utilized for specific purposes or ...
psone emulator 0. 0. In the last 3 months, 5 analysts have offered 12-month price targets for BioNTech. The company has an average price target of $129.0 with a high of $180.00 and a low of $110.00. Below is a ...Analysts have set 12-month price targets for BioNTech, revealing an average target of $145.43, a high estimate of $171.00, and a low estimate of $100.00. This upward trend is evident, with the ... life gamesmerion pa BioNTech Se (BNTX) Q4 2023 Earnings Call Transcript Motley Fool - Wed Mar 20, 1:45PM CDT. BNTX earnings call for the period ending December 31, 2023. BNTX : 93.04 (+1.49%) 3 Stocks Down 30% or More This Year That Wall Street Expects to Skyrocket in 2024 Motley Fool - Mon Dec 18, 2023.We are committed to improving the health of people worldwide with our fundamental research and development of immunotherapies. We believe in scientific rigor, innovation and passion as driving force. BioNTech was founded by scientists and physicians to translate science into survival by combining fundamental research and operational excellence ... rubik cube solving The latest BioNTech stock prices, stock quotes, news, and BNTX history to help you invest and trade smarter.BioNTech Lifts As Covid Sales Plummet With 90% Of Revenue Still To Come. 5/06/2024 BioNTech stock lifted a fraction Monday after Covid vaccine sales dropped again in the first quarter, amid wide ... harbor freihtfitbit luxe bandewr to bahamas The FDA announced late Thursday that it would issue an emergency use authorization (EUA) for Moderna’s COVID vaccine, bringing our immunization arsenal to a total of two. This vacc...Aug 20, 2020 ... NEW YORK & MAINZ, Germany--(BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today shared additional Phase 1 safety and ... cedar cove season 1 On June 6, 2022, Pfizer announced that it was investing $120 million in COVID-19 treatment Paxlovid. On May 3, 2022, Pfizer announced Q1 FY 2022 financial results. Revenue rose 77% year-over-year ... flights from miami to orlandoangle finder calculatorhow do i add a printer Open 84.75. Bid 84.35 x -- Ask 86.05 x -- Day's Range 84.75 - 86.00. 52 Week Range 77.50 - 116.00. Volume 106. Avg. Volume 1,190. Market Cap (intraday) 20.713B. Beta …